BR0308806A - Uso de oxazolidinonas para tratar infecções do tipo pé diabético - Google Patents
Uso de oxazolidinonas para tratar infecções do tipo pé diabéticoInfo
- Publication number
- BR0308806A BR0308806A BR0308806-5A BR0308806A BR0308806A BR 0308806 A BR0308806 A BR 0308806A BR 0308806 A BR0308806 A BR 0308806A BR 0308806 A BR0308806 A BR 0308806A
- Authority
- BR
- Brazil
- Prior art keywords
- diabetic foot
- oxazolidinones
- treat diabetic
- foot infections
- infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36910402P | 2002-03-29 | 2002-03-29 | |
| PCT/US2003/008882 WO2003084534A1 (en) | 2002-03-29 | 2003-03-21 | Parenteral, intravenous, and oral administration of oxazolidinones for treating diabetic foot infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308806A true BR0308806A (pt) | 2005-01-04 |
Family
ID=28791924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308806-5A BR0308806A (pt) | 2002-03-29 | 2003-03-21 | Uso de oxazolidinonas para tratar infecções do tipo pé diabético |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20030216330A1 (https=) |
| EP (1) | EP1490059A1 (https=) |
| JP (1) | JP2005527575A (https=) |
| KR (1) | KR20040095328A (https=) |
| CN (1) | CN1642543A (https=) |
| AU (1) | AU2003223334A1 (https=) |
| BR (1) | BR0308806A (https=) |
| CA (1) | CA2476545A1 (https=) |
| IL (1) | IL164195A0 (https=) |
| MX (1) | MXPA04009356A (https=) |
| NO (1) | NO20044672L (https=) |
| NZ (1) | NZ535648A (https=) |
| PL (1) | PL372661A1 (https=) |
| RU (1) | RU2354372C2 (https=) |
| WO (1) | WO2003084534A1 (https=) |
| ZA (1) | ZA200407734B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200404069A (en) * | 2002-06-28 | 2004-03-16 | Upjohn Co | Difluorothioacetamides of oxazolidinones with a glycoloylpiperazine substituent |
| JP4579502B2 (ja) * | 2003-05-02 | 2010-11-10 | キヤノン株式会社 | 構造体及びその製造方法、該構造体を含むトナー並びにそれを用いた画像形成方法及び装置 |
| US8324398B2 (en) | 2003-06-03 | 2012-12-04 | Rib-X Pharmaceuticals, Inc. | Process for the synthesis of biaryl oxazolidinones |
| JP5043428B2 (ja) | 2003-06-03 | 2012-10-10 | リブ−エックス ファーマシューティカルズ，インコーポレイテッド | ビアリール複素環式化合物ならびにその製造および使用方法 |
| AR046782A1 (es) * | 2003-12-17 | 2005-12-21 | Rib X Pharmaceuticals Inc | Compuestos heterociclicos de biarilo halogenados, composiciones farmaceuticas que los contienen, metodos para su elaboracion y su uso como medicamentos. |
| WO2006008640A1 (en) * | 2004-07-15 | 2006-01-26 | Pharmacia & Upjohn Company Llc | Non-aqueous suspension containing a drug having an unpleasant taste |
| PE20060619A1 (es) * | 2004-07-29 | 2006-07-11 | Ferrer Int | Derivados de oxazolidinona como antibacterianos |
| DE602006019870D1 (de) | 2005-06-08 | 2011-03-10 | Rib X Pharmaceuticals Inc | Verfahren zur synthese von triazolen |
| EP1745784A1 (en) * | 2005-06-27 | 2007-01-24 | Ferrer Internacional, S.A. | Oxazolidinone derivatives and use thereof as antibiotics |
| WO2007000644A1 (en) | 2005-06-29 | 2007-01-04 | Pharmacia & Upjohn Company Llc | Homomorpholine oxazolidinones as antibacterial agents |
| US9427468B2 (en) * | 2007-08-22 | 2016-08-30 | Trustees Of Dartmouth College | Compositions and methods for diagnosing and treating community-acquired methicillin-resistant Staphylococcus aureus |
| UY32493A (es) * | 2009-03-16 | 2010-10-29 | Astrazeneca Ab | " (5r)-3-[4-[1-[(2s)-2,3-dihidroxipropanoil]-3,6-dihidro-2h-piridin-4-il]-3,5-difluorofenil]-5-(isoxazol-3-iloximetil)oxazolidin-2-ona, sus sales farmacéuticamente aceptables, sus ésteres hidrolizables y aplicaciones" |
| US9795601B2 (en) * | 2010-12-15 | 2017-10-24 | Biovista, Inc. | Compositions and methods for cancer treatment |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4705799A (en) * | 1983-06-07 | 1987-11-10 | E. I. Du Pont De Nemours And Company | Aminomethyl oxooxazolidinyl benzenes useful as antibacterial agents |
| US5043443A (en) * | 1988-07-29 | 1991-08-27 | Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives |
| US5254577A (en) * | 1988-07-29 | 1993-10-19 | The Du Pont Merck Pharmaceutical Company | Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents |
| US5182403A (en) * | 1988-09-15 | 1993-01-26 | The Upjohn Company | Substituted 3(5'indazolyl) oxazolidin-2-ones |
| US5225565A (en) * | 1988-09-15 | 1993-07-06 | The Upjohn Company | Antibacterial 3-(fused-ring substituted)phenyl-5β-amidomethyloxazolidin-2-ones |
| US5164510A (en) * | 1988-09-15 | 1992-11-17 | The Upjohn Company | 5'Indolinyl-5β-amidomethyloxazolidin-2-ones |
| US5231188A (en) * | 1989-11-17 | 1993-07-27 | The Upjohn Company | Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents |
| ATE146783T1 (de) * | 1991-11-01 | 1997-01-15 | Upjohn Co | Substituierte aryl- und heteroaryl- phenyloxazolidinone |
| SK283420B6 (sk) * | 1992-05-08 | 2003-07-01 | Pharmacia & Upjohn Company | Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny |
| EP0673370B1 (en) * | 1992-12-08 | 1998-01-07 | PHARMACIA & UPJOHN COMPANY | Tropone-substituted phenyloxazolidinone antibacterial agents |
| US5688792A (en) * | 1994-08-16 | 1997-11-18 | Pharmacia & Upjohn Company | Substituted oxazine and thiazine oxazolidinone antimicrobials |
| EP0730591B1 (en) * | 1993-11-22 | 1999-07-14 | PHARMACIA & UPJOHN COMPANY | Esters of substituted-hydroxyacetyl piperazine phenyl oxazolidinones |
| DE4425612A1 (de) * | 1994-07-20 | 1996-04-04 | Bayer Ag | 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone |
| DE4425609A1 (de) * | 1994-07-20 | 1996-01-25 | Bayer Ag | Benzofuranyl- und Benzothienyloxazolidinone |
| DE4425613A1 (de) * | 1994-07-20 | 1996-01-25 | Bayer Ag | 5-gliedrige Heteroaryl-oxazolidinone |
| DE19514313A1 (de) * | 1994-08-03 | 1996-02-08 | Bayer Ag | Benzoxazolyl- und Benzothiazolyloxazolidinone |
| BR9509673A (pt) * | 1994-11-15 | 1997-09-30 | Upjohn Co | Compostos e uso dos mesmos |
| HRP960159A2 (en) * | 1995-04-21 | 1997-08-31 | Bayer Ag | Benzocyclopentane oxazolidinones containing heteroatoms |
| RU2175324C2 (ru) * | 1995-09-01 | 2001-10-27 | Фармация Энд Апджон Компани | Фенилоксазолидиноны, имеющие с-с-связь с 4-8-членными гетероциклическими кольцами |
| DE19601264A1 (de) * | 1996-01-16 | 1997-07-17 | Bayer Ag | Pyrido-annellierte Thienyl- und Furanyl-Oxazolidinone |
| DE19604223A1 (de) * | 1996-02-06 | 1997-08-07 | Bayer Ag | Neue substituierte Oxazolidinone |
| KR20010015910A (ko) * | 1998-01-23 | 2001-02-26 | 로렌스 티. 마이젠헬더 | 옥사졸리디논 조합 라이브러리, 조성물 및 제조 방법 |
| MY122454A (en) * | 1998-06-05 | 2006-04-29 | Upjohn Co | Use of oxazolidinones for the preparation of a medicament for transdermal delivery |
| ES2245698T3 (es) * | 2000-06-30 | 2006-01-16 | PHARMACIA & UPJOHN COMPANY LLC | Composiciones para el tratamiento de infecciones bacterianas que contienen un compuesto de oxazolidinona, sulbactam y ampicilina. |
-
2003
- 2003-03-21 BR BR0308806-5A patent/BR0308806A/pt not_active IP Right Cessation
- 2003-03-21 NZ NZ535648A patent/NZ535648A/en unknown
- 2003-03-21 WO PCT/US2003/008882 patent/WO2003084534A1/en not_active Ceased
- 2003-03-21 PL PL03372661A patent/PL372661A1/xx not_active Application Discontinuation
- 2003-03-21 MX MXPA04009356A patent/MXPA04009356A/es not_active Application Discontinuation
- 2003-03-21 RU RU2004131830/14A patent/RU2354372C2/ru not_active IP Right Cessation
- 2003-03-21 CA CA002476545A patent/CA2476545A1/en not_active Abandoned
- 2003-03-21 AU AU2003223334A patent/AU2003223334A1/en not_active Abandoned
- 2003-03-21 EP EP03719451A patent/EP1490059A1/en not_active Withdrawn
- 2003-03-21 JP JP2003581774A patent/JP2005527575A/ja not_active Withdrawn
- 2003-03-21 US US10/394,912 patent/US20030216330A1/en not_active Abandoned
- 2003-03-21 IL IL16419503A patent/IL164195A0/xx unknown
- 2003-03-21 KR KR10-2004-7015307A patent/KR20040095328A/ko not_active Ceased
- 2003-03-21 CN CNA038073471A patent/CN1642543A/zh active Pending
-
2004
- 2004-09-23 ZA ZA200407734A patent/ZA200407734B/en unknown
- 2004-10-28 NO NO20044672A patent/NO20044672L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ535648A (en) | 2007-05-31 |
| PL372661A1 (en) | 2005-07-25 |
| CA2476545A1 (en) | 2003-10-16 |
| AU2003223334A1 (en) | 2003-10-20 |
| CN1642543A (zh) | 2005-07-20 |
| KR20040095328A (ko) | 2004-11-12 |
| EP1490059A1 (en) | 2004-12-29 |
| WO2003084534A1 (en) | 2003-10-16 |
| US20030216330A1 (en) | 2003-11-20 |
| RU2004131830A (ru) | 2005-04-10 |
| MXPA04009356A (es) | 2005-01-25 |
| ZA200407734B (en) | 2005-06-24 |
| IL164195A0 (en) | 2005-12-18 |
| NO20044672L (no) | 2004-12-23 |
| RU2354372C2 (ru) | 2009-05-10 |
| JP2005527575A (ja) | 2005-09-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308806A (pt) | Uso de oxazolidinonas para tratar infecções do tipo pé diabético | |
| BRPI0415953A (pt) | formulação de dosagem de liberação controlada oral, método de tratamento de um distúrbio, conjunto de formas de dosagem de liberação controlada e método para administração da formulação | |
| NO20061517L (no) | Langvarig frigivelsesdoseingsform av Ziprasidon | |
| WO2004032909A3 (en) | Stabilized pharmaceutical composition containing basic excipients | |
| BR0315337A (pt) | Composto, formulação farmacêutica, e, método para tratar câncer | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| CO5700796A2 (es) | Composiciones que contienen piperacilina y tazobactam utiles para inyecciones | |
| EA200600540A1 (ru) | Введение лигандов tlr7 и их пролекарств для лечения инфекции вируса гепатита с | |
| BRPI0809011A8 (pt) | composto, composição farmacêutica, método de tratamento, controle ou prevenção de uma doença ou distúrbio, e, forma de dosagem unitária única | |
| BG106906A (bg) | Пуринови производни | |
| EA201000643A1 (ru) | Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| EA200200812A1 (ru) | Фармацевтическая композиция, содержащая низкую дозу энтекавира, и ее применение | |
| CY1106771T1 (el) | Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2 | |
| ES2133324T3 (es) | Compuestos de dibenzoxazepina sustituidos, composiciones farmaceuticas y metodos de uso. | |
| AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
| GT200100063A (es) | El uso de composiciones a base de antibioticos de azalidos para tratar o prevenir una infeccion bacteriana o protozoariaen mamiferos | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| KR970025615A (ko) | 암 전이 억제제 | |
| BRPI0507657A (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo | |
| PL360492A1 (en) | Use of pamoic acid or one of its derivatives, or one of its analogues, for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates | |
| BR0309878A (pt) | Heterotriciclil-6-alquilideno-penemas como inibidores de beta-lactamase | |
| BRPI0508079A (pt) | composto ou uma forma cristalina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, métodos de tratar ou prevenir uma infecção viral com hepatite c em um mamìfero e de inibir replicação de um vìrus da hepatite c | |
| ATE376422T1 (de) | Diclazurilhaltige antiprotozoenmittel | |
| BRPI0407271A (pt) | Composição anti-helmìntica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A, 8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 7A, 8A E 9A ANUIDADES. |